Combination Therapy in the Management of Hypertension: Focus on Angiotensin Receptor Blockers Combined with Diuretics

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2005 Feb 22

PMID 15722654

Citations 6

Authors

Paolo Palatini

Affiliations

Soon will be listed here.

Abstract

There is increasing evidence that combination therapy should be emphasized more than it is at present for the initial treatment of hypertensive patients. Recent guidelines acknowledge the value of combination therapy, although some treatment algorithms fail to echo this message. Observations from major clinical trials in the elderly, diabetics, stroke patients, and African Americans all indicate that combination therapy is necessary to control blood pressure in the majority of these patients. Several combination therapies such as an angiotensin II receptor blocker and a diuretic, an angiotensin-converting enzyme inhibitor with a diuretic, a beta blocker with a diuretic, or an angiotensin-converting enzyme inhibitor with a calcium antagonist have been shown to be effective in patients who do not respond to monotherapy. The current review focuses on the newest such combination; an angiotensin II receptor blocker and a diuretic may have an added advantage of being well tolerated. Recent studies have shown that angiotensin II receptor blockers, given alone or combined with a diuretic, may prevent some cardiovascular outcomes independent of their blood pressure-lowering efficacy.

Citing Articles

Comparative Effectiveness of Angiotensin II Receptor Blockers in Patients With Hypertension in Japan　- Systematic Review and Network Meta-Analysis.

Nakajima T, Oh A, Saita S, Yoshida T, Ohishi M, Nishigaki N Circ Rep. 2021; 2(10):576-586.

PMID: 33693183 PMC: 7932820. DOI: 10.1253/circrep.CR-20-0076.

Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.

Kang M, Kim K, Ihm S, Rhee M, Sohn I, Lee H Trials. 2019; 20(1):389.

PMID: 31262348 PMC: 6604456. DOI: 10.1186/s13063-019-3466-5.

Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study.

Fogari R, Zoppi A, Mugellini A, Preti P, Destro M, Rinaldi A Curr Ther Res Clin Exp. 2014; 69(1):1-15.

PMID: 24692778 PMC: 3969955. DOI: 10.1016/j.curtheres.2008.02.003.

Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.

Huang Q, Sheng C, Li Y, Ma G, Dai Q, Wang J Drugs R D. 2013; 13(2):109-17.

PMID: 23605903 PMC: 3689903. DOI: 10.1007/s40268-013-0013-9.

The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.

Pool J, Glazer R, Crikelair N, Levy D Clin Drug Investig. 2009; 29(12):791-802.

PMID: 19888785 DOI: 10.2165/11530600-000000000-00000.

References

McInnes G, OKane K, Istad H, Keinanen-Kiukaanniemi S, Van Mierlo H . Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000; 14(4):263-9. DOI: 10.1038/sj.jhh.1000997. View

Townsend R, Haggert B, Liss C, Edelman J . Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther. 1995; 17(5):911-23. DOI: 10.1016/0149-2918(95)80069-7. View

Wing L, Reid C, Ryan P, Beilin L, Brown M, Jennings G . A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348(7):583-92. DOI: 10.1056/NEJMoa021716. View

Malacco E, Santonastaso M, Vari N, Gargiulo A, Spagnuolo V, Bertocchi F . Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther. 2004; 26(6):855-65. DOI: 10.1016/s0149-2918(04)90129-4. View

Franco R, Goldflus S, McQuitty M, Oigman W . Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. Blood Press Suppl. 2004; 2:41-7. View

. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967; 202(11):1028-34. View

Black H, Elliott W, Neaton J, Grandits G, Grambsch P, Grimm Jr R . Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. Hypertension. 2001; 37(1):12-18. DOI: 10.1161/01.hyp.37.1.12. View

Gradman A, Brady W, Gazdick L, Lyle P, Zeldin R . A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe.... Clin Ther. 2002; 24(7):1049-61. DOI: 10.1016/s0149-2918(02)80018-2. View

Pepine C, Handberg E, Cooper-DeHoff R, Marks R, Kowey P, Messerli F . A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290(21):2805-16. DOI: 10.1001/jama.290.21.2805. View

10.

. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287):1033-41. DOI: 10.1016/S0140-6736(01)06178-5. View

11.

Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118):1755-62. DOI: 10.1016/s0140-6736(98)04311-6. View

12.

Mallion J, Carretta R, Trenkwalder P, Martinez J, Tykarski A, Teitelbaum I . Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl. 2003; 1:36-43. DOI: 10.1080/08038020310000122. View

13.

Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3. View

14.

Weber M . The ALLHAT report: a case of information and misinformation. J Clin Hypertens (Greenwich). 2003; 5(1):9-13. PMC: 8099274. DOI: 10.1111/j.1524-6175.2003.02287.x. View

15.

Hajjar I, Kotchen T . Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290(2):199-206. DOI: 10.1001/jama.290.2.199. View

16.

Flack J, Saunders E, Gradman A, Kraus W, Lester F, Pratt J . Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther. 2001; 23(8):1193-208. DOI: 10.1016/s0149-2918(01)80101-6. View

17.

Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12):870-8. DOI: 10.1056/NEJMoa011489. View

18.

Conlin P, Elkins M, Liss C, Vrecenak A, Barr E, Edelman J . A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. J Hum Hypertens. 1998; 12(10):693-9. DOI: 10.1038/sj.jhh.1000687. View

19.

. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23):2981-97. DOI: 10.1001/jama.288.23.2981. View

20.

Julius S, Kjeldsen S, Weber M, Brunner H, Ekman S, Hansson L . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426):2022-31. DOI: 10.1016/S0140-6736(04)16451-9. View